Great Bay Bio Invites You to Antibody Engineering & Therapeutics 2024 with Its AI-Powered Drug Development Ecosystem

▲Antibody Engineering & Therapeutics 2024   

This exhibition brings together 900+ antibody scientists and executives from around the globe, along with 75+ leading industry exhibitors.135+ Cutting-edge Technology Speeches in the Industry,125+ Breakthrough Research Posters Aim to Accelerate the Successful Commercialization of Next-Gen Antibody and Protein Drugs.

GBB Team Showcases Intelligent Drug Development Ecosystem at This Conference (Booth No.: 219), Providing Innovative Solutions for Antibody Engineering and Protein Drug Development.The intelligent drug development ecosystem is a culmination of applying cutting-edge technology platforms such as AI, automation, and big data analysis to drive innovation in biopharmaceuticals, empowering the entire process of drug discovery and bioprocess development.It only takes 8 months from target to preclinical product, covering drug discovery, molecular sequence generation and optimization, cell line development, medium development and optimization, etc.Intelligent drug development ecosystem brings revolutionary changes to biopharmaceutical development, especially in the application of bispecific antibodies and ADC drugs, where excellent results have been achieved.The titer of nanobody products reached 13.1g/L, and that of tetrameric bispecific antibody products reached 8.3g/L.

▲GBB Intelligent Drug Development Ecosystem

Antibody Engineering & Therapeutics 2024 Brings Together Over 900 Global Antibody Scientists and Executives, 75+ Leading Industry Exhibitors,135+ World-Class Technical Speeches125+ breakthrough scientific research posters aim to accelerate the successful commercialization of the new generation of antibody and protein drugs, focusing on topics such as bispecific antibodies, ADC, antibody-based cancer, and neurodegenerative disease treatments.